慢性乙型肝炎患者肝内总HBV DNA，cccDNA和血清HBsAg水平分析在

StephenW

Clin Res Hepatol Gastroenterol. 2017 Apr 21. pii: S2210-7401(17)30083-9. doi: 10.1016/j.clinre.2017.03.004. [Epub ahead of print]
Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J1, Sun X2, Fang J3, Wang C4, Han G5, Ren W6.
Author information

1    Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Ji'nan, Shandong 250021, China; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, United States. Electronic address: [email protected].
2    Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Ji'nan, Shandong 250021, China. Electronic address: [email protected].
3    Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Ji'nan, Shandong 250021, China. Electronic address: [email protected].
4    Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Ji'nan, Shandong 250021, China. Electronic address: [email protected].
5    Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Ji'nan, Shandong 250021, China. Electronic address: [email protected].
6    Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Ji'nan, Shandong 250021, China. Electronic address: [email protected].

Abstract
BACKGROUND:

This study aimed to investigate the relationship between intrahepatic cccDNA and serum HBsAg in chronic Hepatitis B (CHB) patients with undetectable serum HBV DNA during antiviral therapy.
METHODS:

We investigated HBsAg serum levels and their relationship to intrahepatic total cccDNA and HBV DNA in CHB patients with undetectable serum HBV DNA during oral antiviral therapy. Intrahepatic cccDNA and HBV DNA quantitation were performed in the same needle biopsy material, while serum HBsAg, HBeAg and HBV DNA levels were measured in samples drawn on the day of the liver biopsy.
RESULTS:

A total of 90 patients who had a liver biopsy were enrolled, including 80 patients with CHB and 10 patients with liver cirrhosis (LC). All the CHB patients were divided into HBeAg-positive and HBeAg-negative group. By using real-time PCR detection, we found that intrahepatic cccDNA and HBV DNA levels were higher in CHB patients than those in LC patients (Intrahepatic cccDNA: 6.15±1.19 vs. 6.12±0.36, HBV DNA: 7.26±0.49 vs. 5.59±0.45, both P<0.05). Intrahepatic cccDNA level was positively correlated with serum HBsAg in HBeAg-negative (r=0.66, P=0.02) and lower serum HBeAg (≤50S/CO) CHB patients (r=0.47, P=0.03), but not in higher serum HBeAg (>50S/CO) CHB patients (both P>0.05). In HBeAg negative patients, serum HBsAg level was correlated with intrahepatic total HBV DNA level (r=0.52, P=0.006). However, no relationship between HBsAg level and intrahepatic total HBV DNA level was found in HBeAg positive patients (both P>0.05).
CONCLUSIONS:

Serum HBsAg can be used to predict intrahepatic cccDNA and HBV DNA level in CHB patients with low serum HBeAg statues, especially in HBeAg negative patients.

Copyright © 2017 Elsevier Masson SAS. All rights reserved.

PMID:
    28438570
DOI:
    10.1016/j.clinre.2017.03.004

StephenW

Clin Res Hepatol Gastroenterol。 2017年4月21日。pii：S2210-7401（17）30083-9。 doi：10.1016 / j.clinre.2017.03.004。 [提前印刷]
慢性乙型肝炎患者肝内总HBV DNA，cccDNA和血清HBsAg水平分析在口服抗病毒治疗期间不可检测血清HBV DNA。
李杰1，孙X2 2，方J 3，王Wang 4，韩G 5，任W6。
作者信息

山东大学附属山东省医院传染病科山东济南市经纬路324号山东250021;美国加利福尼亚州帕洛阿尔托市斯坦福大学医学中心消化内科和肝病科。电子地址：[email protected]。
山东大学附属山东省医院传染病科山东济南市经纬路324号山东250021电子地址：[email protected]。
3山东大学附属山东省医院传染病科山东济南市经纬路324号山东250021。电子地址：[email protected]。
山东大学附属山东省医院肿瘤科4山东济南市经武路324号山东250021。电子地址：[email protected]。
山东大学附属山东省医院感染科，山东济南市经纬路324号山东250021。电子地址：[email protected]。
山东大学附属山东省医院传染病科，山东济南市经纬路324号山东250021。电子地址：[email protected]。

抽象
背景：

本研究旨在探讨抗病毒治疗中不可检测血清HBV DNA的慢性乙型肝炎（CHB）患者肝内cccDNA与血清HBsAg之间的关系。
方法：

我们调查了HBsAg血清水平及其与口服抗病毒治疗中检测不到的血清HBV DNA的CHB患者肝内总cccDNA和HBV DNA的关系。肝脏cccDNA和HBV DNA定量在相同的针活检材料中进行，而在肝活检当天抽取的样品中测量血清HBsAg，HBeAg和HBV DNA水平。
结果：

共纳入了90例肝活检患者，其中包括80例CHB患者和10例肝硬化患者（LC）。所有CHB患者分为HBeAg阳性和HBeAg阴性组。通过实时PCR检测，我们发现CHB患者肝内cccDNA和HBV DNA水平高于LC患者（肝内cccDNA：6.15±1.19 vs. 6.12±0.36，HBV DNA：7.26±0.49 vs. 5.59± 0.45，均P <0.05）。肝内cccDNA水平与HBeAg阴性（r = 0.66，P = 0.02）和血清HBeAg（≤50S/ CO）CHB患者血清HBsAg水平呈正相关（r = 0.47，P = 0.03），但不高于血清HBeAg （> 50S / CO）CHB患者（均P> 0.05）。在HBeAg阴性患者中，血清HBsAg水平与肝内总HBV DNA水平相关（r = 0.52，P = 0.006）。然而，HBeAg阳性患者HBsAg水平与肝内HBV DNA水平之间无相关性（均P> 0.05）。
结论：

血清HBsAg可用于预测低血清HBeAg血症CHB患者肝内cccDNA和HBV DNA水平，特别是HBeAg阴性患者。

版权所有©2017 Elsevier Masson SAS。版权所有。

PMID：
    28438570
DOI：
    10.1016 / j.clinre.2017.03.004